Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone
Drug ID BADD_D02271
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00385
MeSH ID D014221
PubChem ID 31307
TTD Drug ID D03BLF
NDC Product Code 22552-0003; 46439-8701; 38779-0051; 51927-1049
Synonyms Triamcinolone | Volon | Aristocort
Chemical Information
Molecular Formula C21H27FO6
CAS Registry Number 124-94-7
SMILES CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Malignant melanomaSerotransferrinP02787T026173015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
Malignant melanomaInsulinP01308T828413015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.0010.000696%
Hepatomegaly09.01.05.001--Not Available
Hiccups22.02.04.002; 07.01.06.0090.000126%
Hirsutism23.02.04.001; 05.05.01.0050.000126%
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.003--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.000126%
Hyperhidrosis23.02.03.004; 08.01.03.0280.000126%
Hypernatraemia14.05.04.001--
Hypersensitivity10.01.03.0030.000190%
Hypertension24.08.02.0010.000253%
Hypertrichosis23.02.04.002--
Hypertrophic cardiomyopathy03.07.02.004; 02.04.01.002--Not Available
Hypopyon11.01.06.009; 06.04.10.0040.000126%Not Available
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Infection11.01.08.0020.000198%Not Available
Infective myositis15.05.01.003; 11.01.17.0010.000126%
Inflammatory bowel disease07.08.01.0160.000379%Not Available
Influenza22.07.02.001; 11.05.03.0010.000126%Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.0020.000569%
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.0020.000316%Not Available
Joint effusion15.01.02.0050.000126%
Joint stiffness15.01.02.0030.000126%Not Available
Joint swelling15.01.02.0040.000126%Not Available
Lacrimation increased06.08.02.0040.000126%
Leukoderma23.05.02.001--Not Available
Lip dry07.06.01.0030.000190%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages